Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.
Artificial intelligence (AI) is transforming the pharmaceutical industry, revolutionising drug discovery and approval processes, and reshaping how researchers identify potential drug candid
Johnson & Johnson has reported positive phase 3 data with Darzalex in smouldering multiple myeloma (SMM), just before filing applications for the drug in this indication in Europe and t
Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.
As the pharmaceutical industry continues its shift towards more patient-centric models, the incorporation of social determinants of health (SDOH) data has become increasingly valuable.
Alligator Bioscience has reported updated results with its CD40 agonist mitazalimab as a first-line treatment for advanced pancreatic cancer, a disease with few treatment options.<